Granahan Investment Management LLC grew its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 21.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 107,415 shares of the biotechnology company's stock after purchasing an additional 19,160 shares during the quarter. Granahan Investment Management LLC owned about 0.19% of Repligen worth $15,461,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in RGEN. Signaturefd LLC lifted its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in Repligen in the 4th quarter valued at approximately $29,000. Itau Unibanco Holding S.A. bought a new position in shares of Repligen during the fourth quarter worth about $40,000. UMB Bank n.a. raised its position in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its stake in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Insider Activity
In other Repligen news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.20% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Royal Bank of Canada reduced their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.
Get Our Latest Analysis on Repligen
Repligen Stock Performance
NASDAQ RGEN traded down $2.17 during trading hours on Tuesday, hitting $131.55. 546,924 shares of the stock were exchanged, compared to its average volume of 729,574. The company has a market cap of $7.39 billion, a price-to-earnings ratio of -257.94, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The stock has a 50-day moving average of $134.55 and a 200 day moving average of $145.43. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen's revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.28 earnings per share. As a group, equities research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
